The absorption and disposition of single-dose intravenous (i.v.) and oral ranitidine were evaluated in 6 patients undergoing chronic hemodialysis. Ranitidine was given as either 50 mg (0.16 mM) i.v. or 150 mg (0.48 mM) tablets 4 h prior to hemodialysis according to a randomized cross-over design with tests separated by 2 weeks. Following i.v. administration, the peak serum ranitidine concentration was 761 ± 207 µg/l (mean ± SD) and the observed peak after the oral dose was 833 ± 206 µg/l at 3.5 ± 1.2 h. To convert µg/l to µM/1, divide by 314. The terminal elimination rate constants for the i.v. and oral doses were 0.062 ± 0.013 and 0.058 ± 0.004 h-1, respectively, with an apparent volume of distribution of 139.6 ± 35.3 liters and total body clearance 8.5 + 1.6 liters/h for the i.v. dose. Hemodialysis clearances during the i.v. and oral studies were 3.2 ± 0.9 and 3.1 ± 1.0 liters/h, respectively, and the mean amount removed by hemodialysis following i.v. administration was 3.9 ± 2.7 mg. The bioavailability of ranitidine was 54.3 ± 13.5%. Based on these single-dose data, a daily oral dose of 150 mg ranitidine in patients with end-stage renal disease should provide a mean ranitidine serum concentration of approximately 350 µg/l with less than 10% of body stores of ranitidine being lost during any dialysis session.

Keywords:
Ranitidine, H2-receptor antagonist, Hemodialysis, Renal failure, Bioavailability, Pharmacokinetics
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.